CN116096421A - 用于治疗缓解型多发性硬化的方法 - Google Patents

用于治疗缓解型多发性硬化的方法 Download PDF

Info

Publication number
CN116096421A
CN116096421A CN202180051098.1A CN202180051098A CN116096421A CN 116096421 A CN116096421 A CN 116096421A CN 202180051098 A CN202180051098 A CN 202180051098A CN 116096421 A CN116096421 A CN 116096421A
Authority
CN
China
Prior art keywords
compound
subject
per day
cholesterol
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051098.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·贝拉丘
E·卡希尔-麦克法兰
Z·邵
H-H·蔡
R·魏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Massachusetts Co ltd
Original Assignee
Bojian Massachusetts Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bojian Massachusetts Co ltd filed Critical Bojian Massachusetts Co ltd
Publication of CN116096421A publication Critical patent/CN116096421A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
CN202180051098.1A 2020-08-19 2021-08-19 用于治疗缓解型多发性硬化的方法 Pending CN116096421A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067727P 2020-08-19 2020-08-19
US63/067,727 2020-08-19
PCT/US2021/046589 WO2022040369A1 (en) 2020-08-19 2021-08-19 Methods for treating remitting multiple sclerosis

Publications (1)

Publication Number Publication Date
CN116096421A true CN116096421A (zh) 2023-05-09

Family

ID=77693630

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051098.1A Pending CN116096421A (zh) 2020-08-19 2021-08-19 用于治疗缓解型多发性硬化的方法

Country Status (6)

Country Link
US (1) US20230390270A1 (https=)
EP (1) EP4199927A1 (https=)
JP (1) JP2023538065A (https=)
CN (1) CN116096421A (https=)
TW (1) TW202227069A (https=)
WO (1) WO2022040369A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116056702B (zh) * 2020-08-19 2026-01-23 渤健马萨诸塞州股份有限公司 治疗高胆固醇血症的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154925A1 (en) * 2022-02-14 2023-08-17 Genetic Innovations, Inc. Medical spectroscopy and imaging analysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533835A (zh) * 2011-02-07 2014-01-22 比奥根艾迪克Ma公司 S1p调节剂
WO2014018891A1 (en) * 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
CN105026360A (zh) * 2013-01-29 2015-11-04 比奥根Ma公司 S1p调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533835A (zh) * 2011-02-07 2014-01-22 比奥根艾迪克Ma公司 S1p调节剂
WO2014018891A1 (en) * 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
CN105026360A (zh) * 2013-01-29 2015-11-04 比奥根Ma公司 S1p调节剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONALD G. WALKER, 等: "Development of an Early Phase Process for a Potent Oligodendrocyte Precursor Cell Differentiator", ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 28, no. 06, 9 February 2021 (2021-02-09), pages 2203 *
左宗超，等: "新型S1P1受体激动剂西帕莫德的合成", 军事医学 ., vol. 42, no. 10, 9 April 2019 (2019-04-09), pages 762 - 765 *
汤超;秦新月;: "多发性硬化与血脂关系的研究进展", 中国临床研究, vol. 30, no. 03, 31 March 2017 (2017-03-31), pages 408 - 127 *
蒋丽阳;刘文东;袁峰泉;王芳;: "多发性硬化症的药物治疗进展", 医学理论与实践, no. 15, 10 August 2017 (2017-08-10), pages 34 - 36 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116056702B (zh) * 2020-08-19 2026-01-23 渤健马萨诸塞州股份有限公司 治疗高胆固醇血症的方法

Also Published As

Publication number Publication date
WO2022040369A8 (en) 2022-04-14
US20230390270A1 (en) 2023-12-07
WO2022040369A1 (en) 2022-02-24
EP4199927A1 (en) 2023-06-28
TW202227069A (zh) 2022-07-16
JP2023538065A (ja) 2023-09-06

Similar Documents

Publication Publication Date Title
Ziehn et al. Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease
JP7734427B2 (ja) 神経由来エクソソーム中の核酸の検出方法および分析方法
De Vito et al. MiR‐142‐3p regulates synaptopathy‐driven disease progression in multiple sclerosis
US9927437B2 (en) Treating neurodegenerative disease
US12219938B2 (en) Mouse model of alcohol-induced liver cancer
Kou et al. Down-regulation of insulin signaling is involved in painful diabetic neuropathy in type 2 diabetes
Yin et al. Upregulated lncARAT in Schwann cells promotes axonal regeneration by recruiting and activating proregenerative macrophages
CN116096421A (zh) 用于治疗缓解型多发性硬化的方法
WO2020247591A1 (en) Synchronized cell cycle gene expression test for alzheimer's disease
US20110281852A1 (en) Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs
KR20250070087A (ko) 신경변성 질병과 관련된 신경변성의 감소 방법
Adachi et al. Drug discovery research with the iPSC models of neurodegenerative diseases
EP4407315A1 (en) Diagnosis and treatment of neurogenic heterotopic ossification
EP4663193A1 (en) Pharmaceutical composition for prevention or treatment of age-related musculoskeletal disorders
CN114990204B (zh) 一种trex1基因变异引起的疾病的治疗靶点及其应用
Dugger Evaluation of a Precision Medicine Approach for hnRNP U-Related Developmental Epileptic Encephalopathy Using a Mouse Model of Disease
CN117881781A (zh) 用于治疗软骨相关疾病的组合物及其制备方法
Wu et al. A minor muscle stem cell population functions as metabolic Trojan horse fueling systemic aging by succinate induced epigenetic reprogramming
WO2025240566A1 (en) Small molecule steroid receptor coactivator stimulators for use in repairing tissue
EP4501338A1 (en) Pharmaceutical composition containing mir-140 and method for producing same
Sahu Klotho: a paracrine mediator of skeletal muscle regeneration
WO2023079079A1 (en) Methods for treating multiple sclerosis
Scholl Characterisation of white matter pathology in tuberous sclerosis complex and comparison to other malformations of cortical development
English Alterations in the myogenic capacity of satellite cells in a mouse model of ALS
EP3040084A1 (en) Therapeutic agent for ectocornea injury

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination